Alaunos Therapeutics
TCRT
125 hedge funds and large institutions have $128M invested in Alaunos Therapeutics in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 34 increasing their positions, 29 reducing their positions, and 18 closing their positions.
880% more call options, than puts
Call options by funds: $15.7M | Put options by funds: $1.6M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
41% more capital invested
Capital invested by funds: $90.5M → $128M (+$37.6M)
17% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 29
11% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 18
1% more funds holding
Funds holding: 124 → 125 (+1)
0% more ownership
Funds ownership: 0.23% → 0.23% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$4.48M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$2.9M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$2.58M |
| 4 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$1M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
+$880K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$3.28M |
| 2 |
Millennium Management
New York
|
-$2.69M |
| 3 |
Two Sigma Advisers
New York
|
-$1.24M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.24M |
| 5 |
E
Ergoteles
New York
|
-$874K |
TCRT Hedge Fund Activity: Q3 2022 in Review
125 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q3 2022, worth a combined $128M — up 41% from $90.5M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new TCRT positions and 18 closed out — a net gain of 2 holders — while 34 added to existing stakes and 29 trimmed.
The largest buyer was State Street, adding an estimated $4.48M. The largest seller was JP Morgan Chase, cutting an estimated $3.28M.
- 125 institutional investors held Alaunos Therapeutics (TCRT) as of Q3 2022, up from 124 in Q2 2022.
- Funds reported $128M of Alaunos Therapeutics stock for Q3 2022, up 41% quarter-over-quarter.
- 20 funds opened new Alaunos Therapeutics positions in Q3 2022 and 18 closed out, a net change of +2 holders.
- The largest Alaunos Therapeutics buyer in Q3 2022 was State Street, an estimated $4.48M added.
- The largest Alaunos Therapeutics seller in Q3 2022 was JP Morgan Chase, an estimated $3.28M sold.
Based on aggregated 13F filings for Q3 2022.